PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

UK biotech companies raise over £1bn in record quarter

In new data published by the BioIndustry Association (BIA) and Clarivate, UK biotech companies reportedly raised over $1bn in equity finance between June and August 2020.

This makes it the highest quarter for investments in the sector on record and puts the sector on track for its best year ever recorded.

The new report showed that £119m was raised through the year’s first Initial Public Offering, with a further £282m raised through Venture Capital.

Another £601m was raised through other public financings on both London and New York exchanges, demonstrating that biotech share prices continue to perform well on both sides of the Atlantic.

Some notable investments included Freeline Therapeutics, which topped investments with a £119m IPO on NASDAQ and NodThera, which raised £41m in a series B venture capital deal.

“In a year where COVID-19 has caused major disruptions to the global economy it is fantastic to see the strong investment picture for UK biotech continue to gather pace,” said Steve Bates, chief executive of the BIA.

“This strong performance is testimony to the long-term support for life sciences delivered by successive government’s industrial strategies, which have identified the sector as a key engine for economic growth. UK institutional and private investors cannot continue to miss out on this rich source of value creation.

“By building expertise in this sector, a virtuous revolving door can be created where UK institutional and retail investors insightfully support growth opportunities over the medium to longer term, see the returns, and keep coming back for more,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026